An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer

Treatment with the anti‐angiogenic drug bevacizumab in addition to chemotherapy has shown efficacy for breast cancer in some clinical trials, but better biomarkers are needed to optimally select patients for treatment. Here, we present an omics approach where DNA methylation profiles are integrated...

Description complète

Détails bibliographiques

Auteurs principaux:	Thomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, Laxmi Silwal‐Pandit, Anne‐Lise Børresen‐Dale, Ingrid Hedenfalk, Thomas Hatschek, Jörg Tost, Olav Engebraaten, Vessela N. Kristensen
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-08-01
Collection:	Molecular Oncology
Sujets:	bevacizumab breast cancer chemotherapy DNA methylation epigenetics multiomics
Accès en ligne:	https://doi.org/10.1002/1878-0261.13656
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!